08-15-2013, 10:51 PM
So we find here that Belviq (lorcaserin HCl) was the first FDA approved chronic weight management therapy. It is usually given in 10 mg tablets of 60 in a bottle. Belviq, according to its website, is prescribed as an adjunct therapy to reduced-calorie diet and increased physical activity. However it is only indicated for those who are considered obese in their body mass index (BMI) and overweight but having a weight-related co-morbid condition (such as type II diabetes, hypertension, or dyslipidemia).
I wasn’t able to find out what it exactly does to the body, since the exact mechanism of the regulation of appetite is more or less, yet to be known. However, Belviq is said to be a serotonergic and an anorectic as it reacts to receptors in the brain by making the individual have the feeling of satiety to promote weight loss.
It is true that exercise, especially cardio exercise, does good effects to the body, but the team of Belviq believes that there are people who need their drug too.
“Diet, exercise, and behavioral therapy alone may not result in sustained weight loss for many overweight and obese people trying to lose weight,” asserted Lonnel Coats, also the president of Eisai Inc., makers of the drug, “BELVIQ represents an important therapeutic option for physicians responsible for the medical management of their patients who are overweight or obese.”
It has to be used safely as research show that several adverse reactions have occurred in taking Belviq. These are the Serotonin Syndrome or the Neuroleptic Malignant Syndrome (NMS), Valvular Heart Disease, Cognitive Impairment, Psychiatric Disorders, risk for hypoglycemia, Priapism, Pulmonary Hypertension, and others. Hence, such drugs are given in programs or regimens following strict regulations.
For more info, you may visit http://www.belviq.com/pdf/Belviq_Prescri...mation.pdf
Its New Drug Application (NDA) was submitted to the FDA on December 22, 2009. A year after, the FDA voted to recommend its disproval due to the safety risks. Two years later, the FDA panel voted to approve it again after several rounds of studies. It was officially approved on June 27, 2012, but with the above restrictions.
I wasn’t able to find out what it exactly does to the body, since the exact mechanism of the regulation of appetite is more or less, yet to be known. However, Belviq is said to be a serotonergic and an anorectic as it reacts to receptors in the brain by making the individual have the feeling of satiety to promote weight loss.
It is true that exercise, especially cardio exercise, does good effects to the body, but the team of Belviq believes that there are people who need their drug too.
“Diet, exercise, and behavioral therapy alone may not result in sustained weight loss for many overweight and obese people trying to lose weight,” asserted Lonnel Coats, also the president of Eisai Inc., makers of the drug, “BELVIQ represents an important therapeutic option for physicians responsible for the medical management of their patients who are overweight or obese.”
It has to be used safely as research show that several adverse reactions have occurred in taking Belviq. These are the Serotonin Syndrome or the Neuroleptic Malignant Syndrome (NMS), Valvular Heart Disease, Cognitive Impairment, Psychiatric Disorders, risk for hypoglycemia, Priapism, Pulmonary Hypertension, and others. Hence, such drugs are given in programs or regimens following strict regulations.
For more info, you may visit http://www.belviq.com/pdf/Belviq_Prescri...mation.pdf
Its New Drug Application (NDA) was submitted to the FDA on December 22, 2009. A year after, the FDA voted to recommend its disproval due to the safety risks. Two years later, the FDA panel voted to approve it again after several rounds of studies. It was officially approved on June 27, 2012, but with the above restrictions.
![[+]](https://www.biotechnologyforums.com/images/netpen-pro/collapse_collapsed.png)